Becton, Dickinson and Company (NYSE:BDX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Becton, Dickinson and Company (NYSE:BDX) posted its earnings results on Thursday. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09, FiscalAI reports. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.68 EPS. Becton, Dickinson and Company updated its FY 2026 guidance to 12.620-12.720 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• Third-quarter results exceeded expectations, with revenue of $5.0 billion up 4.4%, adjusted operating margin of 24.9%, and adjusted EPS of $3.23, up 4.9%.
• Growth was broad-based, with more than 90% of the portfolio delivering high-single-digit growth and double-digit expansion in biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration, and pharmacy automation. BD also cited share gains and strong momentum from new product launches and targeted commercial investments.
• BD raised the midpoint of its fiscal 2026 adjusted EPS outlook to $12.62–$12.72 and expects revenue growth toward the high end of its low-double-digit FX-neutral range; currency is currently expected to provide an approximately 100-basis-point revenue tailwind.
• Management expects fiscal 2027 revenue growth to remain in the low-single-digit range, partly because the end of Alaris remediation creates an approximately 200-basis-point headwind. Tariffs reduced third-quarter margin by about 110 basis points, while oil, resin costs, and broader market conditions remain risks.
• Year-to-date free cash flow rose 45% to $1.7 billion, supporting $3.1 billion of shareholder returns, including approximately $2.3 billion in share repurchases and $0.9 billion in dividends.

Becton, Dickinson and Company Trading Down 0.3%

Shares of BDX traded down $0.54 during mid-day trading on Friday, reaching $176.53. The company had a trading volume of 1,851,934 shares, compared to its average volume of 1,849,473. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm has a fifty day simple moving average of $154.37 and a 200-day simple moving average of $162.51. The stock has a market cap of $48.64 billion, a price-to-earnings ratio of 53.17, a price-to-earnings-growth ratio of 12.53 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.55 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Quarterly results beat estimates. Fiscal Q3 revenue rose 5.4% year over year to approximately $5.0 billion, exceeding the $4.89 billion consensus estimate. Adjusted EPS of $3.23 also surpassed expectations of $3.14, with growth across BD’s core medical and interventional businesses. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD raised its fiscal 2026 outlook. The company now expects adjusted EPS of $12.62 to $12.72, above the prior outlook and the roughly $12.56 analyst consensus. Management also expects revenue growth toward the high end of its range and is targeting 90% free-cash-flow conversion. Year-to-date operating cash flow increased 33.3% to $2.1 billion, while free cash flow rose 44.6% to $1.7 billion. BD raises FY 2026 adjusted EPS guidance
• Positive Sentiment: Citigroup became more bullish. Citi raised its price target from $198 to $204 and assigned a “buy” rating, implying meaningful upside based on the cited reference price.
• Neutral Sentiment: Analyst views remain divided. Piper Sandler lifted its target to $175 but maintained a “neutral” rating, while Wells Fargo raised its target to $170 and kept an “equal weight” rating. Both targets remain below the cited share price, limiting the positive impact of the revisions.
• Negative Sentiment: Margins and earnings comparisons are concerns. Although revenue and adjusted earnings beat forecasts, margins declined and adjusted EPS fell from $3.68 in the year-earlier quarter. The stock’s elevated valuation may also make investors more sensitive to profitability pressure.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,189 shares of company stock worth $765,661 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BDX. Cambient Family Office LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth $217,000. Compound Planning Inc. lifted its stake in shares of Becton, Dickinson and Company by 72.9% during the fourth quarter. Compound Planning Inc. now owns 2,887 shares of the medical instruments supplier’s stock worth $560,000 after purchasing an additional 1,217 shares in the last quarter. Invesco Ltd. boosted its position in shares of Becton, Dickinson and Company by 48.5% in the fourth quarter. Invesco Ltd. now owns 3,790,490 shares of the medical instruments supplier’s stock worth $735,620,000 after buying an additional 1,237,507 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Becton, Dickinson and Company by 22.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 28,140 shares of the medical instruments supplier’s stock valued at $5,461,000 after buying an additional 5,106 shares in the last quarter. Finally, Andrews Advisory Associates LLC acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at about $253,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BDX. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research note on Friday. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday. Finally, The Goldman Sachs Group reduced their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $185.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.